Board of the Oral Health CRC

Board Member Biographies


Melbourne Laureate Professor Eric Reynolds AO – Chief Executive Officer

PhD Medical Science (University of Melbourne), BSc Hons (University of Melbourne), FICD, FTSE, FRACDS

Melbourne Laureate Professor Eric Reynolds AO is a Board member and Chief Executive Officer of the Oral Health CRC. He is also Head of the Melbourne Dental School at The University of Melbourne.  Professor Reynolds was the Chief Executive Officer of the previous CRC for Oral Health Science, leading the Centre for seven years and through a successful rebid.

On the recommendation of the Honours Committee, The University of Melbourne Council appointed Professor Eric Reynolds a Melbourne Laureate Professor. This honour, rarely bestowed, is reserved for the most distinguished members of academic staff at The University of Melbourne and indicates the extraordinary high standing that Professor Reynolds enjoys within the University of Melbourne and both nationally and internationally.

Professor Reynolds has been a leading figure in oral health science with more than 30 years in dental research, management and commercialisation of innovations. Professor Reynolds is a recipient of the Victoria Prize, in recognition of his work in significantly advancing the State of Victoria’s knowledge base in dental science, and the Anne and Eric Smorgon Memorial Award in recognition of his outstanding contribution to science and technology.

Professor Reynolds was also awarded an Officer of the Order of Australia (AO) for service to community dental health through research and development of preventive and restorative products, to dental education through curriculum development, and as an administrator and teacher. He has lectured and published extensively and chairs or is a member of many professional and university committees and panels.



Professor Mark Hargreaves – University of Melbourne 

BSc (Hons) (University of Melbourne), MA (Ball State University, USA), PhD (University of Melbourne)

Prof Mark Hargreaves is Professor of Physiology and Pro Vice-­Chancellor (Research Partnerships) at The University of Melbourne.  He has BSc (Physiology) and PhD (Physiology) degrees from The University of Melbourne and an MA (Exercise Physiology) from Ball State University (USA).  His research and teaching interests focus on the physiological and metabolic responses to acute and chronic exercise, with emphasis on carbohydrate metabolism.  Current research projects examine the molecular regulation of glucose transporter GLUT4 expression in skeletal muscle and adipose tissue by exercise.  He has authored 120 original scientific articles, 31 review articles and 29 books/book chapters.  He is a Consulting Editor for Journal of Applied Physiology and serves on the editorial boards of the American Journal of Physiology (Endocrinology & Metabolism) and Medicine and Science in Sports and Exercise.  He is a Fellow of the American College of Sports Medicine and Exercise and Sports Science Australia.  He is currently an international representative on the Board of Trustees of the American College of Sports Medicine and is a member of the boards of Bionic Vision Australia, Stem Cells Australia, Melbourne University Sport, and the Victorian Institute of Sport.



Dr Andrew Nash – CSL Limited

PhD Immunology (University of Melbourne), BSc. Hons (University of Melbourne)

Dr Andrew Nash is the Director of Research for CSL Limited, as well as an Honorary Associate Professor at the Bio21 Institute at the University of Melbourne. He has extensive experience in the pharmaceutical / biotechnology sector, including at the CEO level. Dr Nash completed his PhD in immunology at The University of Melbourne in 1988 and, after moving to the Centre for Animal Biotechnology in the Faculty of Veterinary Science, developed and led a research group focused on basic and applied aspects of cytokine biology. In 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics (then Amrad Corporation) as a senior scientist and subsequently held a number of positions including Director of Biologicals Research and Chief Scientific Officer. In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006. Following the acquisition he was appointed as CSL’s Director of Research and currently leads a large team focused on the discovery and development of new recombinant antibody / protein-based medicines to treat serious human disease. Dr Nash is an honorary Associate Professor at the University of Melbourne and is a graduate of the Australian Institute of Company Directors.

Dr Nash has published extensively in peer-reviewed publications and has inventorship on numerous patent filings.


Mr  Futoshi Fusejima – GC Australasia Dental Pty Ltd

BChE (Gunma University, Japan)

Mr Fusejima is the General Manager of the Products Management Department at GC Corporation (Japan) and has more than 25 years’ experience in the research and development of oral care products. He commenced with GC Corporation as a R&D chemist in 1986, and held a range of positions including Senior Scientist and Product Manager before becoming GM of Products Management. Mr Fusejima also spent a number of years working in R&D with GC America Inc.

Mr Fusejima represents GC Australasia Pty Ltd on the Governing Board of the Oral Health CRC. GC Australasia is a wholly owned subsidiary of GC Corporation (Japan), manufacturer of the globally successful Tooth Mousse and Tooth Mousse Plus products. Mr Fusejima oversees the production of a wide range of dental materials and products, including the glass ionomer cement Fuji VII-EP which was developed with technology from the Oral Health CRC.



Mr Chou Chern Yeow– Cadbury Enterprises Pte Ltd

BSc (University of British Columbia)

Mr Chern-Chou Yeow is the Recaldent Business Development Manager at Cadbury Enterprises Pte Ltd, the franchising and key ingredient supply business for Mondelēz International, Asia Pacific region (formerly part of the Kraft Foods Group).   Before this appointment, he headed the Regional Marketing and Sales for Sigma-Aldrich Pte Ltd and was part of the Board of Director for Proligo-Singapore. 

Mr Yeow has worked regionally on projects in Southeast Asian countries, Canada, China and Taiwan.  He comes with more than 10 years’ experience in product development and marketing in the Biotechnology and the Fine Chemical Industry.  Mr Yeow brings valuable experience to the Board in business development planning, strategic analysis and sales process management.  He has a strong industry focus and customer perspective that is highly valued by the Oral Health CRC in the commercialization of its research outputs.